Helen Giza is the new CEO of Fresenius Medical Care; Dr. Carla Kriwet leaves the company
December 05, 2022 at 05:43 pm EST
Share
EQS-Ad-hoc: Fresenius SE & Co. KGaA / Key word(s): Personnel
Helen Giza is the new CEO of Fresenius Medical Care; Dr. Carla Kriwet leaves the company
05-Dec-2022 / 23:40 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Helen Giza is the new CEO of Fresenius Medical Care; Dr. Carla Kriwet leaves the company
Today, the Supervisory Board of Fresenius Medical Care Management AG, the General Partner of Fresenius Medical Care AG & Co. KGaA, has unanimously appointed Helen Giza as CEO of the Management Board with effect as of 6 December 2022. Helen Giza continues to serve as Chief Financial Officer of Fresenius Medical Care until further notice. Her predecessor, Dr. Carla Kriwet is leaving the company at her own request and by mutual agreement due to strategic differences.
As CEO of Fresenius Medical Care, Helen Giza will also join the Management Board of Fresenius Management SE. Dr. Carla Kriwet will leave the Management Board of Fresenius Management SE.
Fresenius SE & Co. KGaA,
represented by Fresenius Management SE,
The Management Board
Bad Homburg v.d.H., December 5, 2022
----------------------------------------
Contact:
Markus Georgi
Senior Vice President Investor Relations & Sustainability
T: +49 (0) 6172 608-2485
markus.georgi@fresenius.com
----------------------------------------
End of Note
05-Dec-2022 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.eqs-news.com
Fresenius SE & Co. KGaA specializes in designing, producing, and selling medical drugs, equipment, and devices used in clinical hospitalization and at home. Net sales break down by activity as follows:
- dialysis treatment (46.9%; Fresenius Medical Care): sales of equipment for hemodialysis, pediatric dialysis, peritoneal dialysis, dialysis services, etc.;
- hospital administration and engineering (34.1%; Fresenius Vamed and Fresenius Helios): management of technical facilities and medical equipment, hospital management, design and production of medical equipment for the pharmaceutical sector, etc.;
- perfusion and clinical nutrition (19%; Fresenius Kabi): sales of parenteral and oral nutrition products, perfusion and vascular filling equipment, transfusion materials, generic injectable products, home medical assistance services in the areas of perfusion, nutrition, and oxygen therapy, etc.
Net sales are distributed geographically as follows: Europe (43.8%), North America (39.4%), Asia/Pacific (10.1%), Latin America (5.4%) and Africa (1.3%).